Wren Kitchens Completes 56% More Customer Appointments and Saves £2 million Annually with Descartes Routing Solution 19-03-2024, 17:45

Io Therapeutics, Inc., presented data from studies of IRX4204, the company’s phase II clinical development stage, highly selective third generation RXR nuclear receptor agonist compound, supporting its potential use for prevention and treatment of normal 10-07-2024, 07:00

RVL Pharmaceuticals plc to Discuss Fourth Quarter and Full 15-03-2023, 17:56